nts. These and other risk factors are more fully
discussed in our Form 10-K for the year ended December 31, 2006, including
under the caption "Risk Factors", and in our other periodic SEC reports,
all of which are available from Maxygen at
http://www.maxygen.com. Maxygen
disclaims any obligation to update or revise any forward-looking statement
contained in this release as a result of new information or future events
or developments.
Selected Consolidated Financial Information
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
Three Months Ended Twelve Months Ended
December 31, December 31,
2007 2006 2007 2006
(unaudited) (unaudited) (Note 1)
Revenues:
Collaborative research and
development revenue $1,756 $5,326 $10,232 $20,544
Revenue from related party 7,696 -- 8,286 --
Grant revenue 1,529 1,184 4,639 4,477
Total revenues 10,981 6,510 23,157 25,021
Expenses:
Research and development 15,338 13,636 59,851 49,130
General and administrative 3,141 4,629 14,951 17,559
Restructuring charges 5,212 -- 5,212 --
Total operating expenses 23,691 18,265 80,014 66,689
Loss from operations (12,710)(11,755) (56,857) (41,668)
Interest income and other
(expense), net 1,436 2,433 7,542 8,524
Equity in net losses of minority
interests -- --
'/>"/>
SOURCE Maxygen, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference2.
Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference3.
Maxygen to Present at the JPMorgan 26th Annual Healthcare Conference4.
Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur5.
Maxygen Reports Third Quarter 2007 Financial Results6.
Maxygen Announces Upcoming Webcasts at Investor Conferences7.
Maxygen Third Quarter 2007 Financial Results Conference Call Notice8.
Maxygen Announces Hold on MAXY-alpha Development Program9.
Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 200710.
AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers11.
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year